Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn

This study has been completed.
Sponsor:
Information provided by:
Takeda
ClinicalTrials.gov Identifier:
NCT00627016
First received: February 21, 2008
Last updated: April 25, 2011
Last verified: April 2011
Results First Received: March 18, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Gastroesophageal Reflux
Interventions: Drug: Dexlansoprazole
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were enrolled at 33 investigative sites in the United States from 07 March 2008 to 20 March 2009.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Subjects eligible for entry into the Treatment Period were randomized into one of two, once-daily (QD) treatment groups.

Reporting Groups
  Description
Placebo Placebo capsules, orally, once daily for up to 4 weeks.
Dexlansoprazole 30 mg QD Dexlansoprazole 30 mg, capsules, orally, once daily for up to 4 weeks.

Participant Flow:   Overall Study
    Placebo   Dexlansoprazole 30 mg QD
STARTED   153   152 
COMPLETED   147   146 
NOT COMPLETED   6   6 
Adverse Event                1                1 
Protocol Violation                0                2 
Lost to Follow-up                0                1 
Withdrawal by Subject                2                1 
Failed Inclusion/Exclusion Criteria                0                1 
Lack of Efficacy                1                0 
Placed on Excluded Drugs                1                0 
Pregnancy                1                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo Placebo capsules, orally, once daily for up to 4 weeks.
Dexlansoprazole 30 mg QD Dexlansoprazole 30 mg, capsules, orally, once daily for up to 4 weeks.
Total Total of all reporting groups

Baseline Measures
   Placebo   Dexlansoprazole 30 mg QD   Total 
Overall Participants Analyzed 
[Units: Participants]
 153   152   305 
Age, Customized 
[Units: Participants]
     
<45 years   75   75   150 
45 to <65 years   76   75   151 
>=65 years   2   2   4 
Age 
[Units: Years]
Mean (Standard Deviation)
 43.9  (12.45)   44.6  (11.29)   44.2  (11.87) 
Gender 
[Units: Participants]
     
Female   98   97   195 
Male   55   55   110 
Region of Enrollment 
[Units: Participants]
     
United States   153   152   305 
Number of Days with Night Heartburn [1] 
[Units: Participants]
     
0-3 days   10   3   13 
4-5 days   36   38   74 
6-7 days   107   111   218 
[1] Baseline diary data were summarized using the non-missing diary entries from Study Day -8 to -2, inclusive.
Number of Nights with Sleep Disturbances Related to Gastroesophageal Reflux Disease (GERD) Symptoms [1] 
[Units: Participants]
     
0-3 Nights   40   33   73 
4-5 Nights   53   47   100 
6-7 Nights   60   72   132 
[1] Baseline diary data were summarized using the non-missing diary entries from Study Day -8 to -2, inclusive.


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Median Percentage of Nights Without Heartburn Over 4 Weeks as Assessed by Daily Diary.   [ Time Frame: 4 Weeks ]

2.  Secondary:   Percent of Subjects With Relief of Night Time Heartburn Over the Last 7 Days of Treatment as Assessed by Daily Diary.   [ Time Frame: Last 7 days of treatment ]

3.  Secondary:   Percentage of Participants With Relief of Gastro-Esophageal Reflux Disease (GERD) Associated Sleep Disturbances Over the Last 7 Days of Treatment as Assessed by Daily Diary.   [ Time Frame: Last 7 days of treatment ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame Adverse events summarized were reported after the first dose of study drug and no more than 30 days after the last dose.
Additional Description Most frequent events are those High Level Terms occurring in at least 5 % of subjects in at least one treatment group.

Reporting Groups
  Description
Placebo Placebo capsules, orally, once daily for up to 4 weeks.
Dexlansoprazole 30 mg QD Dexlansoprazole 30 mg, capsules, orally, once daily for up to 4 weeks.

Serious Adverse Events
    Placebo   Dexlansoprazole 30 mg QD
Total, serious adverse events     
# participants affected / at risk   1/153 (0.65%)   0/152 (0.00%) 
Pregnancy, puerperium and perinatal conditions     
Abortions Spontaneous † 1     
# participants affected / at risk   1/153 (0.65%)   0/152 (0.00%) 
# events   1   0 
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA (12.2)




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information